The Reply - 27/09/22
Doi : 10.1016/j.amjmed.2022.06.008
Anders Holt, MD a, ⁎ 
, Jarl E. Strange, MD a, b, Nina Nouhravesh, MD a, Patricia McGettigan, MD, BSc(Pharm) c, Morten Lamberts, MD, PhD a
, Jarl E. Strange, MD a, b, Nina Nouhravesh, MD a, Patricia McGettigan, MD, BSc(Pharm) c, Morten Lamberts, MD, PhD a a Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark
b Department of Cardiology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
c William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
⁎Requests for reprints should be addressed to Anders Holt, MD, Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Gentofte Hospitalsvej 6, Postbox 635, 2900 Hellerup, Denmark.Department of CardiologyCopenhagen University Hospital – Herlev and GentofteGentofte Hospitalsvej 6, Postbox 635Hellerup2900Denmark
Le texte complet de cet article est disponible en PDF.
| Funding: None. |
|
| Conflicts of Interest: None declared. |
|
| Authorship: All authors have contributed to the preparation of this manuscript. |
© 2022
Elsevier Inc. Tous droits réservés.
Vol 135 - N° 10
P. e407-e408 - octobre 2022 Retour au numéro
Article précédent
- Apixaban for Atrial Fibrillation and Systemic Fluconazole: Bleeding Risk and Possible Preventative Measures
- Tomonari Shimoda, Atsuyuki Watanabe
- Racial Disparities Between C-Reactive Protein and COVID-19 In-Hospital Outcomes
- Wenjin Sun
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?